1.6(top 20%)
2-year impact
2.2(top 20%)
3-year impact
2.5(top 20%)
5-year impact
2.4(top 10%)
10-year impact
20.7K(top 1%)
papers
554.3K(top 1%)
citations
196(top 1%)
h-index
1.7(top 20%)
extended IF
27.9K
all documents
559.4K
doc citations
277(top 2%)
g-index

Top Articles

#TitleJournalYearCitations
1Two pathogenetic types of endometrial carcinomaGynecologic Oncology19831,998
2A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group studyGynecologic Oncology20041,418
3Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A gynecologic oncology group studyGynecologic Oncology19911,152
4A Randomized Trial of Pelvic Radiation Therapy versus No Further Therapy in Selected Patients with Stage IB Carcinoma of the Cervix after Radical Hysterectomy and Pelvic Lymphadenectomy: A Gynecologic Oncology Group StudyGynecologic Oncology19991,043
5Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: A Gynecologic Oncology Group studyGynecologic Oncology1990787
6Prospective assessment of lymphatic dissemination in endometrial cancer: A paradigm shift in surgical stagingGynecologic Oncology2008697
7A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massGynecologic Oncology2009675
8Uterine sarcomas: A reviewGynecologic Oncology2010619
9The Rising Incidence of Adenocarcinoma Relative to Squamous Cell Carcinoma of the Uterine Cervix in the United States—A 24-Year Population-Based StudyGynecologic Oncology2000589
10The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic massGynecologic Oncology2008566
11The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platformGynecologic Oncology2009555
12What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology2006517
13Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysisGynecologic Oncology2012515
14Adenocarcinoma of the Endometrium: Survival Comparisons of Patients with and without Pelvic Node SamplingGynecologic Oncology1995481
15Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigmGynecologic Oncology2009476
16Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening testGynecologic Oncology2015451
17The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group studyGynecologic Oncology1992447
18Complete Cytoreductive Surgery Is Feasible and Maximizes Survival in Patients with Advanced Epithelial Ovarian Cancer: A Prospective StudyGynecologic Oncology1998443
19Surveillance, Epidemiology, and End Results analysis of 2677 cases of uterine sarcoma 1989–1999Gynecologic Oncology2004424
20Therapeutic efficacy of the α-emitter 211At bound on microspheres compared with 90Y and 32P colloids in a murine intraperitoneal tumor modelGynecologic Oncology1992416
21The effect of the α-emitting radionuclide lead-212 on human ovarian carcinoma: A potential new form of therapyGynecologic Oncology1989408
22α-Particle Radiotherapy with 211At-Labeled Monodisperse Polymer Particles, 211At-Labeled IgG Proteins, and Free 211At in a Murine Intraperitoneal Tumor ModelGynecologic Oncology1995407
23Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy☆Gynecologic Oncology2003405
24Natural history and epidemiology of HPV infection and cervical cancerGynecologic Oncology2008404
25Distribution of intraperitoneally injected microspheres labeled with the α-emitter astatine (211At) compared with phosphorus (32P) and yttrium (90Y) colloids in miceGynecologic Oncology1992400
26Uterine Papillary Serous Carcinoma: Patterns of Metastatic SpreadGynecologic Oncology1994394
27Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations — Part IIGynecologic Oncology2016389
28The Wnt/β-catenin pathway in ovarian cancer: A reviewGynecologic Oncology2013382
29Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group studyGynecologic Oncology2008372
30Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulvaGynecologic Oncology1990368
31Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancerGynecologic Oncology2004365
32Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidanceGynecologic Oncology2015364
33Guidelines for pre- and intra-operative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations — Part IGynecologic Oncology2016362
34Folate receptor alpha as a tumor target in epithelial ovarian cancerGynecologic Oncology2008356
35Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancersGynecologic Oncology2008352
36The epidemiology of endometrial cancerGynecologic Oncology1991344
37Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective studyGynecologic Oncology2003342
38Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancerGynecologic Oncology2011342
39The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: Beyond removal of blue nodesGynecologic Oncology2012342
40Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysisGynecologic Oncology2013340
41Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriersGynecologic Oncology2006338
42Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic reviewGynecologic Oncology2003336
43Oncologic and Reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 Adenocarcinoma: A systematic reviewGynecologic Oncology2012336
44A prospective surgical pathological study of stage I squamous carcinoma of the cervix: A Gynecologic Oncology Group studyGynecologic Oncology1989333
45Pathology and epidemiology of HPV infection in femalesGynecologic Oncology2010332
46Class II versus Class III Radical Hysterectomy in Stage IB–IIA Cervical Cancer: A Prospective Randomized StudyGynecologic Oncology2001330
47Comparison of outcomes and cost for endometrial cancer staging via traditional laparotomy, standard laparoscopy and robotic techniquesGynecologic Oncology2008329
48Endometrial cancer: A review and current management strategies: Part IGynecologic Oncology2014328
49Survival after relapse in patients with endometrial cancer: results from a randomized trial☆Gynecologic Oncology2003327
50The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: A 12-year experience at Memorial Sloan-Kettering Cancer CenterGynecologic Oncology2006327